These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36139135)
21. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133 [TBL] [Abstract][Full Text] [Related]
22. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors. Miao L; Zhang Z; Ren Z; Tang F; Li Y Front Immunol; 2021; 12():687822. PubMed ID: 34093592 [TBL] [Abstract][Full Text] [Related]
23. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile. Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094 [TBL] [Abstract][Full Text] [Related]
24. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer. Zhu H; Fang X; Tuhin IJ; Tan J; Ye J; Jia Y; Xu N; Kang L; Li M; Lou X; Zhou JE; Wang Y; Yan Z; Yu L J Cancer Res Clin Oncol; 2022 Sep; 148(9):2261-2274. PubMed ID: 35445870 [TBL] [Abstract][Full Text] [Related]
25. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer. Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A Cells; 2020 Jun; 9(6):. PubMed ID: 32498368 [TBL] [Abstract][Full Text] [Related]
26. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Montalvo MJ; Bandey IN; Rezvan A; Wu KL; Saeedi A; Kulkarni R; Li Y; An X; Sefat KMSR; Varadarajan N Cell Death Dis; 2024 Feb; 15(2):109. PubMed ID: 38307835 [TBL] [Abstract][Full Text] [Related]
27. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
29. CD28-ζ CAR T Cells Resist TGF-β Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop. Golumba-Nagy V; Kuehle J; Hombach AA; Abken H Mol Ther; 2018 Sep; 26(9):2218-2230. PubMed ID: 30055872 [TBL] [Abstract][Full Text] [Related]
30. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669 [TBL] [Abstract][Full Text] [Related]
31. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy. Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339 [TBL] [Abstract][Full Text] [Related]
32. Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells. Grunewald CM; Haist C; König C; Petzsch P; Bister A; Nößner E; Wiek C; Scheckenbach K; Köhrer K; Niegisch G; Hanenberg H; Hoffmann MJ Front Immunol; 2021; 12():782448. PubMed ID: 34868059 [TBL] [Abstract][Full Text] [Related]
33. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma. Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415 [TBL] [Abstract][Full Text] [Related]
34. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199 [TBL] [Abstract][Full Text] [Related]
35. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors. Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641 [TBL] [Abstract][Full Text] [Related]
36. Generation of CAR-T cells using lentiviral vectors. Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998 [TBL] [Abstract][Full Text] [Related]
37. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. Du X; Darcy PK; Wiede F; Tiganis T Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491 [TBL] [Abstract][Full Text] [Related]
38. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631 [TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway. Althaus J; Nilius-Eliliwi V; Maghnouj A; Döring S; Schroers R; Hudecek M; Hahn SA; Mika T Cancer Immunol Immunother; 2023 Aug; 72(8):2573-2583. PubMed ID: 37052701 [TBL] [Abstract][Full Text] [Related]
40. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]